Loading market movers...

Teclistamab

Phase 3

Johnson & Johnson (JNJ)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

18 competitors in Multiple Myeloma

ADPTMRD Testing

CHCTciltacabtagene autoleucel

DFPHCAR T Cell Therapy

View Full Landscape

Drug Information

Target Indication

Multiple Myeloma

Clinical Trial

Last updated: 1/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/23/2022

Tecvayli

Tecvayli is indicated in combination with daratumumab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

PRIME

Drug Science

Mechanism of action & safety profile

Developer

JNJ

Johnson & Johnson

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

galantamine ERPhase 3

Alzheimer's Disease

Test acetaminophenPhase 3

Post-operative Dental Pain

CG 5503;tapentadolPhase 3

Osteoarthritis

tapentadol (CG5503) ERPhase 3

Low Back Pain

levofloxacinPhase 3

Pneumonia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts